All In Biotech

Drug Trial Radar · NCT07409181

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Randomised, Placebo-controlled, Double-blind, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of Oral BI 3000202 in Patients With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

405

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Feb 4, 2029

Study completion Jul 8, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • BI 3000202Drug

    BI 3000202 at different doses

  • PlaceboDrug

    Placebo matching BI 3000202

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of a Systemic Lupus Erythematosus Responder Index (SRI)-4 responseTime frame: At Week 32

Locations

139 sites in 21 countries. Site status is shown where the registry gives one.

  • Wallace & Lee Center

    Beverly Hills, California · Not yet recruiting

  • Arthritis & Osteoporosis Medical Center, Inc - La Palma

    La Palma, California · Recruiting

  • University of California San Diego

    San Diego, California · Not yet recruiting

  • University of California Los Angeles

    Torrance, California · Recruiting

  • Inland Rheumatology Clinical Trials, Inc

    Upland, California · Recruiting

  • Focus Clinical Research

    West Hills, California · Recruiting

  • Denver Arthritis Clinic - Lowry

    Denver, Colorado · Not yet recruiting

  • AARDS Research, Inc.

    Aventura, Florida · Recruiting

  • Meris Clinical Research-Brandon-69466

    Brandon, Florida · Not yet recruiting

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida · Not yet recruiting

  • Integral Rheumatology and Immunology Specialist

    Plantation, Florida · Not yet recruiting

  • Clinical Research of West Florida, Inc. - Tampa

    Tampa, Florida · Recruiting

  • AA MRC LLC - Grand Blanc

    Grand Blanc, Michigan · Not yet recruiting

  • June DO, PC

    Lansing, Michigan · Not yet recruiting

  • Oscar Clinical Trials

    Jackson, Mississippi · Recruiting

  • Boeson Research - Great Falls

    Great Falls, Montana · Recruiting

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina · Not yet recruiting

  • Cross Creek Medical Clinic, PA

    Fayetteville, North Carolina · Recruiting

  • Paramount Medical Research and Consulting

    Middleburg Heights, Ohio · Recruiting

  • Oklahoma Medical Research Foundation

    Oklahoma City, Oklahoma · Recruiting

  • Altoona Arthritis & Osteoporosis Center - Altoona Center for Clinical Research

    Duncansville, Pennsylvania · Recruiting

  • West Tennessee Research Institute

    Jackson, Tennessee · Not yet recruiting

  • Shelby Research LLC

    Memphis, Tennessee · Recruiting

  • Amarillo Center for Clinical Research

    Amarillo, Texas · Recruiting

  • Precision Comprehensive Clinical Research Solutions - Colleyville

    Colleyville, Texas · Recruiting

  • Precision Comprehensive Clinical Research Solutions

    Euless, Texas · Recruiting

  • Arthritis & Rheumatology Institute - Frisco

    Frisco, Texas · Recruiting

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Not yet recruiting

  • R&H Clinical Research - Katy

    Katy, Texas · Recruiting

  • SouthWest Rheumatology Research

    Mesquite, Texas · Not yet recruiting

  • Centro Medico Reumatologico - OMI

    CABA, Argentina · Recruiting

  • Instituto de Investigacion Clinica TyT

    CABA, Argentina · Recruiting

  • Instituto Medico Especializado

    Capital Federal, Argentina · Recruiting

  • Consultora integral en Salud SRL.

    General Paz, Argentina · Recruiting

  • Sanatorio Maipu

    Maipu, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Quilmes

    Quilmes, Argentina · Recruiting

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • SAPIENS - Instituto de Estudos e Pesquisa Clinica

    Curitiba, Brazil · Recruiting

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.